Grant ID | PP160097 |
Awarded On | August 17, 2016 |
Title | School-Based Human Papillomavirus Vaccination Program in the Lower Rio Grande Valley |
Program | Prevention |
Award Mechanism | Evidence-Based Prevention Programs and Services |
Institution/Organization | The University of Texas Medical Branch at Galveston |
Principal Investigator/Program Director | Ana Rodriguez |
Cancer Sites | Cervix Uteri |
Contracted Amount | $747,727 |
Lay Summary |
The HPV vaccine reduces the morbidity and mortality of HPV-related diseases, including anogenital warts and cervical, oropharyngeal, vulvar, vaginal, penile, and anal cancer.[1-9] Guidelines recommend HPV vaccination for girls and boys aged 11–12, with catch-up doses for ages 13–26.[7,9] We will use the 9-valent HPV vaccine, which covers 5 additional HPV cancer-causing types and is estimated to prevent 15% more cervical cancer than the quadrivalent vaccine. The 3-injection HPV vaccine series has to be given in early adolescence to maximize effectiveness. It provides the greatest benefit to adolescents before they become sexually active.[30] The Healthy People 2020 goal is to vaccinate ... |